High risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR
|
|
- Randolph Riley
- 6 years ago
- Views:
Transcription
1 DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient (anticipated duration > 10 days) Give posaconazole prophylaxis -see appendix two Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR *see below for additional information Note; Galactomanan sensitivity may be reduced in pts on posaconazole or beta lactam antibiotics If patient becomes pyrexial - Start antibiotics as per the neutropenic sepsis guidelines - Look for source (see other investigations below) - Review the fungal screening blood test results Positive fungal screen -start ambisome and arrange HRCT chest Negative fungal screen and persistent pyrexia after 48 hours of antibiotics -switch to second line antibiotics and arrange HRCT chest If suggestive of fungal infection arrange bronchoscopy for BAL HRCT chest, if suggestive of fungal infection arrange bronchoscopy for BAL and start Ambisome If HRCT chest, is clear and negative fungal screen, continue second line antibiotics Other investigations (indicate on the request forms that the patient is neutropenic) Blood cultures central and peripheral (taken simultaneously) MSU Sputum sample Oral swabs for bacterial, fungal and viral cultures if mouth ulcers /mucositis Culture any skin lesions Chest X-ray CT sinuses if symptomatic Consider CT or US abdomen if hepato(splenic) candidiasis is suspected
2 Samples Specimen required One serum sample in a red top bottle with a minimum volume of 1ml (1.5ml is preferred) is required. BAL can also be sent for Galactomanan testing. Days of the week to be sent Twice a week, Monday and Wednesday Test interpretation Galactomanan in serum >0.5 is reported as detected. Confirm the first result with another sample. Galactomanan in BAL >0.5 is reported as detected; however most use a higher value i.e.>1 index as a cut off. Beta-D Glucan in serum >80 pg/ml is reported as detected. Results <60 pg/ml are not detected pg/ml is equivocal. Confirm the first result with another sample. Aspergillus PCR will be reported as detected or not detected. For all tests clinical correlation is advised. Prophylaxis High risk neutropenic patients (AML, high risk myelodysplasia, or where anticipated duration of neutropenia is > 10 days) should be given oral posaconazole for prophylaxis. See appendix two for full information on dosing and monitoring. Fluconazole prophylaxis (100mg daily) can be given to lower risk patients Risk factors for invasive fungal infection (IFI) Of the patients managed in Derby, those at highest risk are patients with AML, prolonged neutropenia, and history of corticosteroid use. Other risk factors are iron overload, treatment with purine analogues or monoclonal antibodies, renal failure, concurrent CMV infection and advanced age. Causative pathogens Until a few years ago, Candida spp were responsible for the majority of invasive fungal infections, but there has been a shift over time in the prevalent pathogens such that moulds are now a more common cause of IFI in severely immunocompromised patients, with Aspergillus spp being the most common. Other moulds causing IFI include Zygomycetes, Fusarium spp, and Scedosporium spp. There has also been a shift from Candida albicans to non-albican Candida spp.
3 Microbiological isolation of fungi is rarely achieved, so treatment is usually empirical, based on the clinical presentation and radiological investigations. The majority of cases will be probable and possible IFI. MICROBIOLOGY HOST FACTORS CLINICAL FACTORS Positive cytology or culture from BAL or sputum or sinus aspirate or other source Prolonged use steroids e.g. at an average min dose equivalent of prednisolone 0.3mg/kg/day for >3 weeks Neutropenia (<0.5 for >10days) Recipient of an allogeneic stem cell transplant T-cell immunosuppressant therapy, e.g Campath, ciclosporin Inherited immunodeficiency disorder, eg. Severe combined immunodeficiency CT chest findings nodules or wedge-shaped infiltrates, halo sign, air crescent sign or cavity Pleural rub or pleurisy or haemoptysis In sinus infection acute localized pain, nasal ulcer, black eschar Opthalmic signs seek ophthalmology review urgently CNS disease focal lesions or meningeal enhancement on CT/ MRI Abscesses in liver and/or spleen PROVEN (Histopathology/ cytopathology/ of fine needle aspirate or biopsy showing yeast or mould OR positive blood culture) PROBABLE 1 microbiological +1 host factor + 1 clinical factor POSSIBLE 1 host +1 clinical factor (but no microbiology evidence) Empirical Treatment Liposomal amphotericin (Ambisome ) (prescribe by brand name - see note 1 below) Dose 3mg/kg/day in 250ml dextrose 5% infused over minutes. Due to the risk of anaphylaxis and allergic reactions, a test dose should be given. Give 1mg of the first dose over 10 minutes. Then wait for 30 minutes, and provided no reaction, the rest of the 3mg/kg dose can be given over minutes. Contra-indications to Liposomal amphotericin (Ambisome ) Hypersensitivity to the active substance or any of its constituents. Cautions with Liposomal amphotericin (Ambisome ) Renal impairment - If clinically significant reduction in renal function occurs, consideration should be given to dose reduction, treatment interruption or discontinuation. Hepatic impairment Pregnancy and breastfeeding - discuss with pharmacist Drug interactions see BNF Notes 1 As a result of fatalities due to confusion between different brands and formulations of amphotericin, always ensure you are certain that you are prescribing, preparing or administering the intended brand, formulation and dose of amphotericin. If there is any doubt, DO NOT PROCEED. Seek advice from medical/nursing and/or pharmacy staff.
4 In patients with hypersensitivity to liposomal amphotericin, or where lipsomal amphotericin is unsuitable use caspofungin Dosing of caspofungin 70mg on first day, then 50mg once daily. If body weight >80kg, continue with 70mg daily. Infuse over 60 minutes in 250ml sodium chloride 0.9%. In moderate liver disease, give 70mg on day one, then reduce to 35mg daily. There is no experience with caspofungin in severe liver disease, so avoid if possible (see note 2 below). Contra-indications to caspofungin Breast feeding, hypersensitivity to the active substance or any of its constituents. Cautions with caspofungin Avoid in pregnancy unless essential toxicity in animal studies. Drug interactions see BNF 2 Anidulafungin is another echinocandin which does not require dosage adjustment in severe hepatic impairment. However, it is only licensed for invasive candidiasis Place in therapy for Voriconazole For the management of suspected invasive fungal infections in patients who are intolerant to or have a documented hypersensitivity to amphotericin and caspofungin or any of their components. OR Proven CNS invasive fungal infection caused by fungi sensitive to voriconazole, due to its superior CNS penetration. OR For the management of patients who have responded well and are fit to discharge but need to finish a treatment course Route Voriconazole intravenous Voriconazole oral (bioavailability 96%) Dose 6mg/kg every 12 hours for 2 doses then 4mg/kg every 12hours by intravenous infusion. If 40kg, 400mg every 12 hours for 2 doses. Then 200mg every 12 hours. If <40kg: 200mg every 12hours for 2doses. Then 100mg every 12 hours Contra-indications Acute porphyria, breast feeding, pregnancy unless potential benefit outweighs risk Cautions Renal Impairment In patients with moderate to severe renal dysfunction (Creatinine clearance <50 ml/min), accumulation of the intravenous vehicle occurs. Oral voriconazole should be administered to these patients, unless an assessment of the risk-benefit to the patient justifies the use of intravenous voriconazole. Serum creatinine levels should be closely monitored in these patients and, if increases occur, consideration should be given to changing to oral voriconazole therapy. Hepatic impairment Reduce dose (see SPC). No information in severe cirrhosis. Monitor LFTS increased risk of hepatic reactions in haematological malignancy
5 Arrhythmias or QT interval prolongation Caution with concomitant drugs that prolong QT interval see BNF. Drug Interactions Many significant interactions. See BNF and contact member of pharmacy team for further advice Duration of treatment Duration of therapy should be based on the patient's clinical response Proven, probable or possible invasive fungal infection Discuss duration of treatment with a consultant microbiologist. Generally patients should be treated for a minimum of 14 days and treatment should continue for at least 7 days after neutropenia and clinical symptoms/ signs are resolved. Refractory cases Any radiological changes should have either resolved or shown no deterioration after the minimum 14 days of treatment. If there is inadequate response after this time, or sooner if evidence of progression discuss with a consultant microbiologist regarding increasing the ambisome dose to 5mg/kg, changing treatment, and/or adding a second agent
6 References 1. British Committee for Standards in Haematology (2008) Guidelines on the management of invasive fungal infection during therapy for haematological malignancy Johansen HK, Gøtzsche P Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia (Cochrane review 2000, last updated 2007) 3. Oto et al (2007) Amphotericin B deoxycholate use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. Mycoses 2007;50(2): Walsh T, Sable C, de Pauw, Donowitz G, Maertans J, Baden L, Bourque M, Lupinacci R, Nguyen BY, Teppler H(2004) Liposomal Amphoteracin B for empirical therapy in patients with persistent fever and neutropenia. New England Journal of Medicine, 351, Walsh T, Sable C, de Pauw B, Donowitz G, Maertens J, Baden L, Bourque M, Lupinacci R, Nguyen BY, Teppler H. (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. New England Journal of Medicine, 351, Journal of Antimicrobial Chemotherapy Pathways for managing invasive fungal disease in immunocompromised patients 2011:66(supp 1) De Pauw et al revised definitions of invasive fungal disease from the EORTC/MSG consensus group Clinical Infectious Disease 2008;46: Documentation control Development of Guidelines: Approved By; Consultant microbiologists Consultant haematologists Antimicrobial D+T subgroup Approval Date: July 2015 Review history and changes Reviewed 26/11/2014 and review date extended to 30/4/15 pending review of the testing and diagnostic strategy and impending change to prophylaxis regime. Appendix II updated in line with itraconazole updated guideline. 2/2/15 posaconazole replaced itraconazole for prophylaxis. Included as an appendix in this guideline Next review Date: July 2016 July new diagnostic algorithm to incorporate galactomanan and BD-glucan screening. Key Contact: Dr Allotey consultant haematologist Dr Milind Khare Consultant microbiologist
7 Appendix I Posaconazole Dosing and monitoring Information for prophylactic use in selected haematology patients Patient group Primary prophylaxis in patients with prolonged neutropenia due to chemotherapy for Acute Myeloid Leukaemia and High risk Myelodysplasia Primary prophylaxis post autograft (these patients are currently managed in Nottingham) Preparation: Dose for tablets Duration Side effects (For full list see BNF and SPC) Drug Interactions (See BNF and SPC for full list) Dosing in renal and hepatic impairment Commence on admission for chemotherapy and continue for 7 days after neutrophils recover to >0.5 Posaconazole 100mg TABLETS (Note: tablets are preferred as they achieve much better plasma levels than the suspension. The suspension should only be used in patients who cannot take tablets. THE DOSE IS NOT THE SAME see section on suspension below) 300mg twice daily on day one, then 300mg once daily. With the tablets, it does not matter when the dose is taken in relation to food Continue for 7 days after neutrophils recover to >0.5 To be stopped if a patient develops a breakthrough fungal infection and commences treatment for this. In such scenarios it would then be more appropriate for secondary prophylaxis during further courses of chemotherapy to be with Ambisome 1mg/kg Mon, Wed and Fri. Particular adverse effects to note are; Gastrointestinal e.g. nausea, abdominal pain, diarrhoea. Posaconazole may cause hepatotoxicity. Monitor LFTs before and during treatment. Patient should be told how to recognise signs of liver disorder Posaconazole is extensively metabolised by the CYP 34A system. There are many significant drug interactions with posaconazole. The patient s concurrent medication list should be checked carefully against Appendix 1 of the BNF and /or the SPC before prescribing posaconazole. For further advice discuss with a pharmacist. Posaconazole may prolong the QT interval and should be used with caution with other drugs known to do this. In addition, potassium, calcium and magnesium levels should be monitored before and during treatment. No dosage adjustment required, but use with caution in hepatic impairment.
8 Posaconazole suspension Monitoring of levels The suspension is not interchangeable with the tablets and should only be used in patients who cannot take tablets as it is not as well absorbed and does not reach such high plasma levels. The dose of suspension is 200mg three times a day, and it must be taken during or immediately after a meal. Absorption is much better following a high fat meal. Levels are not necessary in patients taking tablets unless; There are particular concerns about absorption e.g. vomiting and diarrhoea. The patient is on concomitant medication which may significantly affect the levels. The patient weighs >120kg Due to erratic absorption of posaconazole from the suspension formulation, levels should be checked to ensure they have reached a therapeutic level. If a level is needed, it should be taken pre-dose on day 5-7. Levels are sent to Bristol and will usually take 2-3 days to be reported. The target pre-dose level for prophylaxis is >0.7mg/l Development of Guidelines: Consultation With: Approved By; Dr Allotey Consultant haematologist Julia Lacey Antimicrobial Pharmacist Consultant haematologists Consultant microbiologists Drugs and Therapeutics Committee Version 1 approval Date: 26/1/2015 Review Date: Key Contact: 1/2/2016 Audit: After 12 months of implementation, an audit of tolerance and effectiveness will be carried out. Dr Allotey Consultant haematologist Julia Lacey Antimicrobial Pharmacist References (for posaconazole) BNF No 68 Summary of Product Characteristics accessed 14/1/15 Mycology reference laboratory service users guide PHE Bristol July 2014
PAGL Inclusion Approved at January 2017 PGC
Guideline for the prophylaxis and treatment of fungal infections in Haematology patients 1. Introduction PAGL Inclusion Approved at January 2017 PGC Haematology, CHUGGS June 2016 This guideline sets out
More informationHAEMATOLOGY ANTIFUNGAL POLICY
HAEMATOLOGY ANTIFUNGAL POLICY PROPHYLAXIS Primary Prophylaxis Patient Group Patients receiving intensive remissioninduction chemotherapy for Acute Leukaemia (excluding patients receiving vinca alkaloids)
More informationNeutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationAntifungal therapy guidelines
Background Invasive fungal infections (IFI) can cause significant morbidity and mortality among patients with haematological malignancies. There is good evidence for the use of antifungal prophylaxis in
More informationFungal Infections: Reporting. Marcie Tomblyn, MD, MS Associate Member, Moffitt Cancer Center
Fungal Infections: Management and Reporting Marcie Tomblyn, MD, MS Associate Member, Moffitt Cancer Center February 25, 2010 Objectives Review common fungal infections in HCT patients Review current available
More informationTitle: Author: Speciality / Division: Directorate:
Antifungal guidelines for CANDIDIASIS INFECTIONS (Adults) Proven infection: Targeted antifungal therapy should be prescribed for: o Positive cultures from a sterile site with clinical or radiological abnormality
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More information2046: Fungal Infection Pre-Infusion Data
2046: Fungal Infection Pre-Infusion Data Fungal infections are significant opportunistic infections affecting transplant patients. Because these infections are quite serious, it is important to collect
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationMicafungin, a new Echinocandin: Pediatric Development
Micafungin, a new Echinocandin: Pediatric Development Andreas H. Groll, M.D. Infectious Disease Research Program Center for Bone Marrow Transplantation and Department of Pediatric Hematology/Oncology University
More informationMycophenolate Mofetil (MMF)
SCG: For Transplant patients The following guidelines are designed to provide information relating to mycophenolate mofetil and to outline the responsibilities of the primary and secondary care teams in
More informationCase Studies in Fungal Infections and Antifungal Therapy
Case Studies in Fungal Infections and Antifungal Therapy Wayne L. Gold MD, FRCPC Annual Meeting of the Canadian Society of Internal Medicine November 4, 2017 Disclosures No financial disclosures or industry
More informationFungal Infection Post-Infusion Data
Fungal Infection Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / Visit: 100 day 6 months 1 year 2 years >2 years. Specify: CIBMTR Form 2146 revision
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationFungal Infection Pre-Infusion Data
Fungal Infection Pre-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: Event date: / / CIBMTR Form 2046 revision 5 (page 1 of 5). Last Updated May, 2018. Infection Episode
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationTrust Guideline for the Use of Antifungals in Adults
For Use in: By: For: Division responsible for document: Key words: Name of document author: Job title of document author: Name of document author s Line Manager: Job title of author s Line Manager: Supported
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationA Care Pathway exists for the management of neutropenic fever. Copies of the care pathway document are available in EAU, A&E, Deanesly and CHU.
Subject: Neutropenic Fever Guideline for Junior Doctors Date of Implementation: January 2010 Date of Review: January 2012 Director Responsible for Implementation and Review: Policy location: Consultant
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationAn Update in the Management of Candidiasis
An Update in the Management of Candidiasis Daniel B. Chastain, Pharm.D., AAHIVP Infectious Diseases Pharmacy Specialist Phoebe Putney Memorial Hospital Adjunct Clinical Assistant Professor UGA College
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationCondition First line Alternative Comments Candidemia Nonneutropenic adults
Recommendations for the treatment of candidiasis. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Condition First line Alternative
More informationEMPIRICAL PRESCRIBING GUIDELINES FOR SYSTEMIC FUNGAL INFECTIONS IN ADULTS - HH (1)/CL(G)/651/13
Hampshire Hospitals NHS Foundation Trust Empirical Antifungal Prescribing Guidelines [INSERT UNIQUE POLICY IDENTIFIER] Due for latest review on January 2015. CHECK THE INTRANET FOR LATEST VERSION EMPIRICAL
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationanidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd
Scottish Medicines Consortium Re-Submission anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 10 October 2008 The Scottish Medicines Consortium
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationHYDROXYCARBAMIDE for Haematological conditions (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: HYDROXYCARBAMIDE for Haematological conditions (Adults) Indication: Hydroxycarbamide is an established treatment in haematological
More informationHOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS?
HOW TO DEFINE RESPONSE IN ANTIFUNGAL CLINICAL TRIALS? EORTC IFICG START Look for Help? MORTALITYASSOCIATED WITH INVASIVE ASPERGILLOSIS Lin et al. Clin Infect Dis 2001;32:358 100 % 50 n = 178 0 0 60 120
More informationFLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1)
FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1) AML19 Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome ***Refer to trial protocol
More informationGemcitabine + Capecitabine (ESPAC-4 Trial)
Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationScottish Medicines Consortium
Scottish Medicines Consortium anidulafungin 100mg powder and solvent for concentrate for solution for infusion (Ecalta ) No. (465/08) Pfizer Ltd 09 May 2008 The Scottish Medicines Consortium (SMC) has
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationMANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSP There are no translations available. MANAGEMENT OF FEVER IN PEDIATRIC PATIENTS FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationHigh Intensity Chemotherapy Guidelines for Haematology Patients at ASPH
High Intensity Chemotherapy Guidelines for Haematology Patients at ASPH Contents: Page No. 1. Overview 2 2. Admission 3 3. Admission Checklist 5 4. Inpatient management during chemotherapy 6 5. Inpatient
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationVoriconazole 200 mg powder for solution for infusion 03 Jun version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Voriconazole 200 mg powder for solution for infusion 03 Jun. 2015 version 3.0 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Voriconazole
More informationFungal Infection in the ICU: Current Controversies
Fungal Infection in the ICU: Current Controversies Andrew F. Shorr, MD, MPH, FCCP, FACP Washington Hospital Center Georgetown University, Washington, DC Disclosures I have served as a consultant to, researcher/investigator
More informationTrust Guideline. for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis. (*ie aged 16 years and over)
Trust Guideline for Ciclosporin Treatment & Monitoring for Adult* Patients with Acute, Severe Ulcerative Colitis (*ie aged 16 years and over) abc A guideline recommended for use In: Gastroenterology/Medical
More informationMATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab)
MATRIX (Methotrexate, Cytarabine, Thiotepa and Rituximab) Indication First line treatment of primary CNS lymphoma. ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 and 6 Rituximab
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationUpdate on Antifungal Stewardship
Update on Antifungal Stewardship Dr Jacqueline Sneddon, MRPharmS Scottish Antimicrobial Prescribing Group Antimicrobial Management Team event 7 th November 2017 ANTIFUNGAL STEERING GROUP CHAIR Prof Brian
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationCisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer
Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationHydroxychloroquine (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationFungal infection in the immunocompromised patient. Dr Kirsty Dodgson
Fungal infection in the immunocompromised patient Dr Kirsty Dodgson Aims Discuss different types of fungi Overview of types of clinical infections Clinical Manifestations Fungus Includes Moulds Aspergillus
More informationFludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study
Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes. ***See protocol for further details*** Available for Routine Use in
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationESCMID Online Lecture Library. by author
How To Best Use Antifungal Agents Cornelia Lass-Flörl Division of Hygiene and Medical Microbiology Innsbruck Medical University ESCMID SUMMER SCHOOL 2012 Epidemiology Diagnosis Roadmap Antifungal drugs
More informationGuideline for the Management of Fever and Neutropenia in Children with Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation
Guideline for the Management of Fever Neutropenia in Children with Cancer /or Undergoing Hematopoietic Stem-Cell Transplantation COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationPanobinostat, Bortezomib and Dexamethasone
Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory
More informationBreast Pathway Group Everolimus in Advanced Breast Cancer
Breast Pathway Group Everolimus in Advanced Breast Cancer Indication: Hormone receptor positive, HER2 negative advanced breast cancer National Cancer Drug Fund criteria: ER+ve, HER2 ve metastatic breast
More informationALL MAINTENANCE (25-60 years)
ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationAntifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco 3/3 blood cultures are positive for an unidentified
More informationDERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:
OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationAntifungal Update. Candida: In Vitro Antifungal Susceptibility Testing
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More information(R) CHOEP. May be used for stage IA - IV Diffuse Large B Cell non-hodgkin lymphoma in combination with rituximab.
(R) CHOEP Indication Treatment of stage IA - IV T cell non-hodgkin lymphoma as an alternative to CHOP in younger, fitter patients with normal LDH level. May be used for stage IA - IV Diffuse Large B Cell
More informationSkin Pathway Group Alemtuzumab in Cutaneous Lymphoma
Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant
More informationFludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia
DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Dose Route Diluent Rate 1 Paracetamol 1gram Oral 1 Hydrocortisone 100mg IV bolus 1 Chlorphenamine 10mg IV bolus 1 Rituximab 375mg/m 2 IV infusion
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationCarfilzomib and Dexamethasone (CarDex)
Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationFLUCAND HIKMA PHARMACEUTICALS
09-15 FLUCAND HIKMA PHARMACEUTICALS (Fluconazole) Description Flucand is a crystalline white - whitish powder, which is slightly soluble in water and in a saline solution. Its molecular weight is 306.3.
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma. TREATMENT INTENT Palliative or curative depending on context.
More informationR-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin
: Rituximab, Gemcitabine, Dexamethasone &Cisplatin INDICATION Relapsed or refractory Hodgkin and non-hodgkin lymphoma. Omit Rituximab for patients with Hodgkin Lymphoma or high grade T cell non-hodgkin
More informationWhen is failure failure?
When is failure failure? Bart-Jan Kullberg, M.D. Radboud University Nijmegen The Netherlands The ICU patient with candidemia!! Female, 39 years old!! Multiple abdominal surgeries for Crohn's disease!!
More informationFOLFIRINOX (pancreas)
FOLFIRINOX (pancreas) Indication First or second line chemotherapy for metastatic pancreatic cancer. Eligible patients must be
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationElements for a Public Summary. [Product Name] 40 mg/ml oral suspension. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a Public Summary [Product Name] 40 mg/ml oral suspension VI.2.1 Overview of disease epidemiology Fungi (yeasts) are small organisms that feed by breaking down tissue. In humans, fungi
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationAntifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?
Antifungal Update B. Joseph Guglielmo, Pharm.D. Professor and Chair Department of Clinical Pharmacy School of Pharmacy University of California San Francisco The patient spikes a new fever and 3/3 blood
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More information